A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
OBJECTIVE
To evaluate fludarabine in patients with chronic lymphocytic leukaemia (CLL) not responding to standard treatment.


METHODS
Fludarabine was administered for 5 consecutive days and repeated 4-weekly.


METHODS
Seventeen patients at a single institution were treated.


METHODS
Objective remission was seen in 11 patients. The median survival time was 356 days.


CONCLUSIONS
Fludarabine is an effective treatment for patients with advanced CLL.
Hocepied
A M
AM
Department of Medical Oncology, University of Pretoria.
Falkson
C I
CI
Falkson
G
G
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine